Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan plus fluzoparib for second-line recurrent metastatic small cell lung cancer
ChiCTR2400089985Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome and fluzoparib in small cell lung cancer (SCLC), sponsored by Renji Hospital. Primary endpoint: objective response rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
irinotecan liposomefluzoparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400089985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089985.